[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"memory-disorder\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:memory-disorder":30},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,48],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":20,"enrollmentInfo":21,"targetDuration":4,"studyType":24,"phases":25,"briefSummary":27,"conditions":28,"keywords":31,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":37,"lastUpdatePostDateStruct":38,"startDateStruct":41,"completionDateStruct":43,"leadSponsor":45,"locationsCount":5},"100607641","how-do-patients-with-amnesia-acquire-new-knowledge-100607641",false,"NCT07191197","How do Patients With Amnesia Acquire New Knowledge?","New Semantic Learning in Patients With Selective Brain Lesions in Temporal Regions: a Behavioural and MRI Study","ASSAM","Inclusion Criteria:\n\n* Patients aged between 18 and 70 years\n* Living in France since less than 20 years, being able to understand the French language, and have basic cultural knowledge as evaluated in classical clinical consultation\n* Written agreement to participate in the study\n* Intellectual capacities compatible with the cognitive tasks and signing of consent\n* Affiliation to the French social security system\n* For patients: bilateral brain lesion of the medial temporal lobe or the extended hippocampal system\n\nExclusion Criteria:\n\n* Subjects under the age of 18 or over 70\n* Contraindications for MRI (examples: wearers of a pacemaker or cardiac defibrillator, implanted equipment activated by an electrical, magnetic or mechanical system, wearers of haemostatic clips for intracerebral aneurysms or carotid arteries, wearers of orthopedic implants, claustrophobic)\n* Refusal to be informed of an anomaly detected during the MRI",true,"ALL","18 Years","70 Years",{"count":22,"type":23},150,"ESTIMATED","INTERVENTIONAL",[26],"NA","THE STUDY AIMS to constitute the largest group of patients with major memory impairment resulting from various etiology and specific lesions of the medial temporal lobe (MTL) and use a combined psychometric and neuroimaging approach to study the factors allowing these patients to successfully learn new semantic information.",[29,30],"Amnesia","Memory Disorder",[32,33,34,35],"Learning","Semantic memory","Hippocampus","Temporal pole","RECRUITING","2026-05-07",{"date":39,"type":40},"2026-05-08","ACTUAL",{"date":42,"type":40},"2026-04-08",{"date":44,"type":23},"2030-01-31",{"name":46,"class":47},"University Hospital, Toulouse","OTHER",{"id":49,"slug":50,"hasResults":11,"nctId":51,"briefTitle":52,"officialTitle":53,"acronym":4,"eligibilityCriteria":54,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":55,"enrollmentInfo":56,"targetDuration":4,"studyType":24,"phases":58,"briefSummary":60,"conditions":61,"keywords":66,"overallStatus":70,"whyStopped":4,"lastUpdateSubmitDate":42,"lastUpdatePostDateStruct":71,"startDateStruct":73,"completionDateStruct":75,"leadSponsor":77,"locationsCount":79},"100610496","early-phase-1-cholinergic-enhancement-of-theta-100610496","NCT07228338","Cholinergic Enhancement of Theta","Muscarinic Agonist Modulation of Memory Processing Oscillatory Activity","Inclusion Criteria:\n\n1. Age 18 - 75 years, all races\u002Fethnicities, and both genders are eligible.\n2. Candidates for pre-operative evaluation using stereo intracranial electrodes and admission to the Epilepsy Monitoring Unit (EMU) as determined independently by the patient's treating physician as part of the patient's routine medical care.\n3. Able to read, understand, and provide written, dated informed consent prior to screening.\n4. In good general health, aside from a history of epilepsy, as ascertained by medical history, physical examination (PE), clinical laboratory evaluations, and ECG.\n\nExclusion Criteria:\n\n1. Has a clinically significant abnormality on the screening physical examination that might affect safety, study participation, or confound interpretation of study results according to the study physician.\n2. Female that is pregnant, breastfeeding, or has a positive pregnancy test at screening or baseline. We note that pregnant patients are excluded from undergoing iEEG.\n3. Hepatic impairment (moderate or severe).\n4. Renal impairment (moderate or severe).\n5. Clinically significant bladder outlet obstruction or incomplete bladder emptying, such as patients with prostatic hyperplasia (BPH), diabetic cystopathy, pre-existing urinary retention.\n6. History of hypersensitivity to COBENFY or trospium chloride (angioedema risks).\n7. Untreated narrow-angle glaucoma.\n8. Biliary Disease (symptomatic gallstones, gallbladder disorders, pancreatitis).\n9. Strong Inhibitors of CYP2D6 such as fluoxetine, paroxetine, bupropion, terbinafine.\n10. Sensitive Substrates of CYP3A4 such as buspirone, eletriptan.\n11. Narrow Therapeutic Index Substrates of P-glycoprotein such as digoxin, colchicine, apixaban.\n12. Drugs Eliminated by Active Tubular Secretion.\n13. Antimuscarinic Drugs such as diphenhydramine, benztropine, oxybutynin.","75 Years",{"count":57,"type":23},50,[59],"EARLY_PHASE1","The goal of this study is to learn about the effects of Cobenfy KarXT (xanomeline and trospium chloride) on episodic memory processing, including specific effects on areas of the brain involved in memory and changes it may have on brain activity. The investigators will do this by testing epileptic patients who are already undergoing intracranial surgery for seizure monitoring, and measuring the activity from the brain areas being assessed.\n\nThe main questions it aims to answer are 1) whether Cobenfy KarXT changes memory activity based on its agonist effect on muscarinic receptors and acetylcholine, and 2) what the nature of these brain activity changes are. This work builds on previous experiments evaluating cholinergic antagonists.\n\nParticipants will complete two treatment arms. One of these will be with the drug, and the other will be with a placebo pill, so that the participants are unaware which session the actual drug has been received. Patients will complete a verbal serial recall and\u002For associative recognition task each of the two days. An anesthesiologist or patient nurse will administer either the drug or the placebo at a critical point which addresses both of the research questions.\n\nResearchers will compare the brain activity between the two treatment arms to determine what brain activity changes, and whether there is an additional behavioral effect on memory.",[62,63,64,30,65],"Epilepsy","Seizures","Cognitive Impairment, Mild","Memory Loss",[67,68,69],"oscillatory changest","cholinergic agonist","muscarinic agonist","NOT_YET_RECRUITING",{"date":72,"type":40},"2026-04-09",{"date":74,"type":23},"2026-10",{"date":76,"type":23},"2031-10",{"name":78,"class":47},"University of Texas Southwestern Medical Center",1]